title: Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy.
abstract: Efficacy of gemcitabine and docetaxel (GEM + DOC) chemotherapy in patients with recurrent or refractory osteosarcoma was evaluated.
  
  
  
  Data of 53 patients from 9 institutions, who received GEM (675 or 900 mg/m(2) on days 1 and 8) and DOC (100 mg/m(2) on day 8), were retrospectively reviewed.
  
  
  
  GEM + DOC was administered as adjuvant (n = 25) or palliative chemotherapy (n = 28). Patients received a median 3 courses (range, 1-10 courses). Objective response rate (CR + PR, where CR is complete response and PR is partial response) and disease control rate (CR+ PR + SD, where SD is stable disease) were 14.3% and 28.6%, respectively. Disease control rate was higher in patients receiving 900 mg/m(2) GEM than in patients receiving 675 mg/m(2) (50.0% vs. 12.5%, P = 0.03). Higher GEM dose was associated with better survival, both in adjuvant (1-year overall survival, 90.9 ± 8.7% vs. 38.5 ± 13.5%, P = 0.002) and palliative settings (50.0 ± 14.4% vs. 31.3 ± 11.6%, P = 0.04).
  
  
  
  Further studies are necessary to investigate the efficacy of more aggressive and higher doses of GEM + DOC chemotherapy in osteosarcoma.
authors.affiliation: Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Republic of Korea.
authors.forename: Jun Ah
authors.initials: JA
authors.lastname: Lee
authors.affiliation: Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Republic of Korea.
authors.forename: Dae-Geun
authors.initials: DG
authors.lastname: Jeon
authors.affiliation: Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Republic of Korea.
authors.forename: Wan Hyeong
authors.initials: WH
authors.lastname: Cho
authors.affiliation: Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Republic of Korea.
authors.forename: Won Seok
authors.initials: WS
authors.lastname: Song
authors.affiliation: Department of Pediatrics, Kyung Hee University School of Medicine, Seoul, Republic of Korea.
authors.forename: Hoi Soo
authors.initials: HS
authors.lastname: Yoon
authors.affiliation: Center for Pediatric Oncology, National Cancer Center, Goyang, Seoul, Republic of Korea.
authors.forename: Hyeon Jin
authors.initials: HJ
authors.lastname: Park
authors.affiliation: Center for Pediatric Oncology, National Cancer Center, Goyang, Seoul, Republic of Korea.
authors.forename: Byung Kiu
authors.initials: BK
authors.lastname: Park
authors.affiliation: Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Seoul, Republic of Korea.
authors.forename: Hyoung Soo
authors.initials: HS
authors.lastname: Choi
authors.affiliation: Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Seoul, Republic of Korea.
authors.forename: Hyo Seop
authors.initials: HS
authors.lastname: Ahn
authors.affiliation: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
authors.forename: Ji Won
authors.initials: JW
authors.lastname: Lee
authors.affiliation: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
authors.forename: Keon Hee
authors.initials: KH
authors.lastname: Yoo
authors.affiliation: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
authors.forename: Ki Woong
authors.initials: KW
authors.lastname: Sung
authors.affiliation: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
authors.forename: Hong Hoe
authors.initials: HH
authors.lastname: Koo
authors.affiliation: Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
authors.forename: Hyoung Jin
authors.initials: HJ
authors.lastname: Kang
authors.affiliation: Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
authors.forename: Kyung Duk
authors.initials: KD
authors.lastname: Park
authors.affiliation: Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
authors.forename: Hee Young
authors.initials: HY
authors.lastname: Shin
authors.affiliation: Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
authors.forename: Kyung-Nam
authors.initials: KN
authors.lastname: Koh
authors.affiliation: Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
authors.forename: Ho Joon
authors.initials: HJ
authors.lastname: Im
authors.affiliation: Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
authors.forename: Jong Jin
authors.initials: JJ
authors.lastname: Seo
authors.affiliation: Department of Pediatrics, Chungnam National University College of Medicine, Daejon, Republic of Korea.
authors.forename: Yeon Jung
authors.initials: YJ
authors.lastname: Lim
authors.affiliation: Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea.
authors.forename: Hee Jo
authors.initials: HJ
authors.lastname: Baek
authors.affiliation: Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea.
authors.forename: Hoon
authors.initials: H
authors.lastname: Kook
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002648:Child; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000093542:Gemcitabine
keywords: docetaxel; gemcitabine; osteosarcoma; recurrent; refractory